Oral Modified-Release Minoxidil for Hair Loss Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for hair loss, such as topical minoxidil, often result in adverse effects and require frequent application, lacking a controlled release mechanism to maintain effective serum levels for sustained hair regrowth.
Innovation Solution
A modified release formulation of minoxidil or its pharmaceutically acceptable salt, designed for oral administration, which releases 50% to 98% of the daily dose within 12 hours, achieving a Tmax of 30 to 360 minutes and a Cmax of 0.25 ng/ml to 20 ng/ml, minimizing adverse effects and maintaining therapeutic levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical minoxidil is used for hair loss treatment, then hair regrowth can be achieved, but adverse effects occur and frequent application is required
Solution Approach 1:
The patent changes the pharmacokinetic parameters of minoxidil by using a modified release formulation that controls the release rate, achieving sustained serum levels between 0.25-20 ng/ml over 24 hours. This parameter change allows the drug to maintain therapeutic efficacy while reducing peak-related adverse effects
Solution Approach 2:
The modified release formulation provides continuous release of minoxidil throughout the day, maintaining stable serum concentrations. This continuous action eliminates the need for frequent dosing while ensuring consistent therapeutic effect for hair regrowth
2Duration of action of moving object
If topical minoxidil is applied frequently to maintain effective serum levels, then sustained hair regrowth can be achieved, but treatment compliance decreases
Solution Approach 1:
The formulation provides continuous drug release over 24 hours through controlled release mechanisms, maintaining therapeutic serum levels without requiring multiple daily applications. This single-dose continuous release significantly improves patient compliance
Solution Approach 2:
The modified release formulation creates a periodic dosing regimen where one daily dose provides sustained release throughout the day, replacing the need for multiple frequent applications and simplifying the treatment schedule
3Reliability
If a modified release formulation releases 50% to 98% of the daily dose within 12 hours, then therapeutic levels are maintained, but the release rate must be precisely controlled
Solution Approach 1:
The patent defines specific release parameters (50-98% within 12 hours, Tmax of 30-360 minutes, Cmax of 0.25-20 ng/ml) that optimize the balance between therapeutic efficacy and manufacturing feasibility. These parameter ranges provide clear targets for quality control during manufacturing
4Object-affected harmful factors
If the formulation achieves a Cmax of 0.25 ng/ml to 20 ng/ml, then adverse effects are minimized, but the concentration control becomes more challenging
Solution Approach 1:
The patent establishes a therapeutic window for Cmax (0.25-20 ng/ml) that is wide enough to accommodate normal manufacturing variations while still preventing adverse effects. This parameter range balances safety with manufacturing practicality
Data Source
AI summary
The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.